Medical Devices

A new deal brings a breakthrough blood cancer therapy, Zemcelpro®, closer to Canada. But for patients with few options, the 2028 timeline is a stark reminder of the gap between innovation and access.

As new drugs outpace manufacturing capacity, a French giant bets on local production in China to build the supply chains of tomorrow's therapies.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

A new study by SciBase and Castle Biosciences is testing technology to predict atopic dermatitis flares, promising a shift from reactive care to patient control.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Carestream's new Lux HD detectors blend high-res imaging, AI, and rugged design to boost diagnostics, streamline workflows, and challenge market rivals.

Mickey Mikitani shifts to Executive Chairman, installing a new CEO to navigate the high-stakes journey from visionary science to U.S. market reality.

Takeda seeks FDA approval for its gut-focused drug ENTYVIO in children, a major step toward a new era of treatment for the rising tide of pediatric IBD.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

Medmovie's move to a browser-based platform for its cardiac visuals isn't just a tech upgrade; it's a strategic push to democratize health literacy.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

A silent disease affects 54 million Americans and is set to cost $95 billion by 2030. Now, 33 states are taking action against the osteoporosis epidemic.

Mosaic Clinical Technologies launches an AI-native platform that assists radiologists in real time, aiming to boost capacity and fight burnout in a strained field.

Dana-Farber's historic $50M Yawkey grant funds more than a building; it fuels a new era of integrated research and patient-centric cancer treatment.

Capsa Healthcare's acquisition of The Harloff Company isn't just another merger; it's a strategic play to build an end-to-end healthcare solutions empire.

A new FDA-cleared laser offers a drug-free option for millions with tennis elbow. But does the science justify the cost and will patients have access?

A Phase 1 trial launch is more than a milestone; it's a look at the future of pharma, where AI-driven speed and strategic global partnerships converge.

With the hire of Dr. David Feygin, Outcome Capital signals a major bet on AI-driven advisory, reflecting a broader arms race in healthcare finance.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

The genomics firm is unveiling two technologies aimed at slashing errors and automating key steps in DNA sequencing, a move that could reshape lab economics.